Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia
Authors: Roman-Gomez, J. (José)
Jimenez-Velasco, A. (A.)
Castillejo, J.A. (J.A.)
Aguirre, X. (Xavier)
Barrios, M. (M.)
Navarro, G. (Germán)
Molina, F.J. (Francisco J.)
Calasanz, M.J. (María José)
Prosper, F. (Felipe)
Heiniger, A. (A.)
Torres, A. (Antonio)
Keywords: Materias Investigacion::Ciencias de la Salud::Oncología
Issue Date: 2004
Publisher: American Society of Hematology
Publisher version: http://dx.doi.org/10.1182/blood-2004-03-0954
ISSN: 0006-4971
Citation: Roman-Gomez, J., Jimenez-Velasco, A., Castillejo, J. A., Agirre, X., Barrios, M., Navarro, G. et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 140(8): 2492-2498
Abstract
Promoter hypermethylation plays an important role in the inactivation of cancerrelated genes. This abnormality occurs early in leukemogenesis and seems to be associated with poor prognosis in acute lymphoblastic leukemia (ALL). To determine the extent of hypermethylation in ALL, we analyzed the methylation status of the CDH1, p73, p16, p15, p57, NES-1, DKK-3, CDH13, p14, TMS-1, APAF-1, DAPK, PARKIN, LATS-1, and PTEN genes in 251 consecutive ALL patients.Atotal of 77.3% of samples had at least 1 gene methylated, whereas 35.9% of cases had 4 or more genes methylated. Clinical features and complete remission rate did not differ among patients without methylated genes, patients with 1 to 3 methylated genes (methylated group A), or patients with more than 3 methylated genes (methylated group B). Estimated disease-free survival (DFS) and overall survival (OS) at 11 years were 75.5% and 66.1%, respectively, for the nonmethylated group; 37.2% and 45.5% for methylated group A; and 9.4% and 7.8% for methylated group B (P < .0001 and P .0004, respectively). Multivariate analysis demonstrated that the methylation profile was an independent prognostic factor in predicting DFS (P < .0001) and OS (P .003). Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in ALL
Permanent link: http://hdl.handle.net/10171/18564
Appears in Collections:DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:
File:  2004_Blood_Roman-Gomez_Promoter hypermethylation of cancer-related genes is a strong independent prognostic factor in acute lymphoblastic leukemia.pdf
Description: 
Size:  121,21 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.